FibroGen lays off 75% of US staff as cancer drug flunks 2 more trials

cafead

Administrator
Staff member
  • cafead   Jul 31, 2024 at 10:22: AM
via FibroGen is radically restructuring its business, laying off 75% of its U.S. staff and stopping investment in its lead candidate in response to the failure of two late-phase pancreatic cancer clinical trials.

article source
 

<